Men with prostate cancer who are treated with testosterone-lowering drugs are twice as likely to develop dementia within five years as prostate cancer patients whose testosterone levels are not tampered with, research shows.
(The JAMA Network Journals) Androgen deprivation therapy is a mainstay of prostate cancer treatment. ADT has shown survival benefit in some patients but it also has been associated with some adverse health effects and a possible lin...
Reducing testosterone levels with androgen deprivation therapy, or A.D.T., more than doubles the risk of dementia.
Men treated with androgen deprivation therapy - a hormone therapy - for prostate cancer may be more than twice as likely to develop dementia, study finds.
Androgen Deprivation Therapy, a common hormone therapy to treat prostate cancer, may double a man's risk of dementia, regardless of his age, Penn Medicine researchers reported.